Mo1055: COST-EFFECTIVENESS ANALYSIS OF SUBCUTANEOUS INFLIXIMAB FOR INFLAMMATORY BOWEL DISEASES IN SEQUENCIAL BIOLOGICAL TREATMENT

Detalles Bibliográficos
Autores principales: Baik, Deborah, Atreya, Raja, Bouhnik, Yoram, Casey, Daniel, Jang, Minyoung, Yoon, SangWook, Kwon, Taek S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AGA Institute. Published by Elsevier Inc. 2022
Materias:
AGA Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212299/
http://dx.doi.org/10.1016/S0016-5085(22)61588-9
_version_ 1784730551585865728
author Baik, Deborah
Atreya, Raja
Bouhnik, Yoram
Casey, Daniel
Jang, Minyoung
Yoon, SangWook
Kwon, Taek S.
author_facet Baik, Deborah
Atreya, Raja
Bouhnik, Yoram
Casey, Daniel
Jang, Minyoung
Yoon, SangWook
Kwon, Taek S.
author_sort Baik, Deborah
collection PubMed
description
format Online
Article
Text
id pubmed-9212299
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher AGA Institute. Published by Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-92122992022-06-22 Mo1055: COST-EFFECTIVENESS ANALYSIS OF SUBCUTANEOUS INFLIXIMAB FOR INFLAMMATORY BOWEL DISEASES IN SEQUENCIAL BIOLOGICAL TREATMENT Baik, Deborah Atreya, Raja Bouhnik, Yoram Casey, Daniel Jang, Minyoung Yoon, SangWook Kwon, Taek S. Gastroenterology AGA Abstracts AGA Institute. Published by Elsevier Inc. 2022-05 2022-06-16 /pmc/articles/PMC9212299/ http://dx.doi.org/10.1016/S0016-5085(22)61588-9 Text en Copyright © 2022 AGA Institute. Published by Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle AGA Abstracts
Baik, Deborah
Atreya, Raja
Bouhnik, Yoram
Casey, Daniel
Jang, Minyoung
Yoon, SangWook
Kwon, Taek S.
Mo1055: COST-EFFECTIVENESS ANALYSIS OF SUBCUTANEOUS INFLIXIMAB FOR INFLAMMATORY BOWEL DISEASES IN SEQUENCIAL BIOLOGICAL TREATMENT
title Mo1055: COST-EFFECTIVENESS ANALYSIS OF SUBCUTANEOUS INFLIXIMAB FOR INFLAMMATORY BOWEL DISEASES IN SEQUENCIAL BIOLOGICAL TREATMENT
title_full Mo1055: COST-EFFECTIVENESS ANALYSIS OF SUBCUTANEOUS INFLIXIMAB FOR INFLAMMATORY BOWEL DISEASES IN SEQUENCIAL BIOLOGICAL TREATMENT
title_fullStr Mo1055: COST-EFFECTIVENESS ANALYSIS OF SUBCUTANEOUS INFLIXIMAB FOR INFLAMMATORY BOWEL DISEASES IN SEQUENCIAL BIOLOGICAL TREATMENT
title_full_unstemmed Mo1055: COST-EFFECTIVENESS ANALYSIS OF SUBCUTANEOUS INFLIXIMAB FOR INFLAMMATORY BOWEL DISEASES IN SEQUENCIAL BIOLOGICAL TREATMENT
title_short Mo1055: COST-EFFECTIVENESS ANALYSIS OF SUBCUTANEOUS INFLIXIMAB FOR INFLAMMATORY BOWEL DISEASES IN SEQUENCIAL BIOLOGICAL TREATMENT
title_sort mo1055: cost-effectiveness analysis of subcutaneous infliximab for inflammatory bowel diseases in sequencial biological treatment
topic AGA Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212299/
http://dx.doi.org/10.1016/S0016-5085(22)61588-9
work_keys_str_mv AT baikdeborah mo1055costeffectivenessanalysisofsubcutaneousinfliximabforinflammatoryboweldiseasesinsequencialbiologicaltreatment
AT atreyaraja mo1055costeffectivenessanalysisofsubcutaneousinfliximabforinflammatoryboweldiseasesinsequencialbiologicaltreatment
AT bouhnikyoram mo1055costeffectivenessanalysisofsubcutaneousinfliximabforinflammatoryboweldiseasesinsequencialbiologicaltreatment
AT caseydaniel mo1055costeffectivenessanalysisofsubcutaneousinfliximabforinflammatoryboweldiseasesinsequencialbiologicaltreatment
AT jangminyoung mo1055costeffectivenessanalysisofsubcutaneousinfliximabforinflammatoryboweldiseasesinsequencialbiologicaltreatment
AT yoonsangwook mo1055costeffectivenessanalysisofsubcutaneousinfliximabforinflammatoryboweldiseasesinsequencialbiologicaltreatment
AT kwontaeks mo1055costeffectivenessanalysisofsubcutaneousinfliximabforinflammatoryboweldiseasesinsequencialbiologicaltreatment

Ejemplares similares